FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment Xiaoping SongWei TangJing Li PRECLINICAL STUDIES 07 April 2021 Pages: 1201 - 1212
Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers Meng-Zhu LiTao MengJin-Xue He PRECLINICAL STUDIES 12 March 2021 Pages: 1213 - 1221
A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells Jinbing XueGang WuShuying He PRECLINICAL STUDIES 31 March 2021 Pages: 1222 - 1231
Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer Nurul A AbdullahMartyn InmanStewart G Martin PRECLINICAL STUDIES Open access 25 March 2021 Pages: 1232 - 1241
Identification of novel inhibitors of GLUT1 by virtual screening and cell-based assays Xiaotong ChenYunshuo ZhaoJiangfeng Du PRECLINICAL STUDIES 26 April 2021 Pages: 1242 - 1255
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model Yuki FujiiHirofumi KamachiAkinobu Taketomi PRECLINICAL STUDIES 27 April 2021 Pages: 1256 - 1266
Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models Fanyi MengYinshuang ChenWeipeng Wang PRECLINICAL STUDIES 28 April 2021 Pages: 1267 - 1274
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study María Eugenia OlmedoMartin ForsterEmiliano Calvo PHASE I STUDIES Open access 11 March 2021 Pages: 1275 - 1283
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors Gerald S. FalchookMarc PeetersDaniel A. Peterson PHASE I STUDIES 14 April 2021 Pages: 1284 - 1297
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study Katrina S. PedersenPatrick M. GriersonBenjamin Tan PHASE I STUDIES 18 March 2021 Pages: 1298 - 1305
Effect of severe renal impairment on the pharmacokinetics of brigatinib Neeraj GuptaMichael J. HanleyKarthik Venkatakrishnan PHASE I STUDIES Open access 20 March 2021 Pages: 1306 - 1314
Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers Ming-Mo HouChing-Liang HoXiaodi Zhang PHASE I STUDIES Open access 13 March 2021 Pages: 1315 - 1323
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations Sarina A. Piha-PaulAnalía AzaroAntoine Hollebecque PHASE I STUDIES Open access 27 March 2021 Pages: 1324 - 1334
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer Hyehyun JeongYong Sang HongTae Won Kim PHASE I STUDIES 07 April 2021 Pages: 1335 - 1347
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer Filip JankuPatricia LoRussoHoward A. Ball PHASE I STUDIES 08 April 2021 Pages: 1348 - 1356
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study Kyaw Zin TheinSarina A. Piha-PaulAung Naing PHASE I STUDIES Open access 28 April 2021 Pages: 1357 - 1365
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations Jii Bum LeeMinkyu JungHyun Cheol Chung PHASE II STUDIES Open access 15 March 2021 Pages: 1366 - 1374
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma Stephen L. ChanPaul N.M. ChengAnthony W.H. Chan PHASE II STUDIES Open access 15 April 2021 Pages: 1375 - 1382
The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinoma Peng YuanFei WangBaoan Chen REVIEW 22 March 2021 Pages: 1383 - 1388
The drug lag issue: a 20-year review of China Xiaoyu LiYue Yang REVIEW 30 April 2021 Pages: 1389 - 1398
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer Hiroto InoueAkiko TodakaHirofumi Yasui SHORT REPORT Open access 09 April 2021 Pages: 1399 - 1404
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial Andrew W. HahnJad ChahoudAung Naing SHORT REPORT 26 March 2021 Pages: 1405 - 1410
Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review Hui SuChao YuQingcui Song SHORT REPORT 25 March 2021 Pages: 1411 - 1418
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation Lin-ling JinZhen-zhen WuXin Zhao Short Report 09 April 2021 Pages: 1419 - 1421
Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real‐world treatment outcomes Masahide FukudoKeiko AsaiNobuhiro Ueno Short Report 08 April 2021 Pages: 1422 - 1431
Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab Yong WangJun XuRongjie Tao Short Report 13 April 2021 Pages: 1432 - 1435
Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer Ming-jun ZhangDong-sheng ChenCong-jun Zhang SHORT REPORT 29 April 2021 Pages: 1436 - 1438
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma Chen XiongZhihuai WangDousheng Bai Clinical trial methodologies 03 May 2021 Pages: 1439 - 1453
Comment on “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma” Jiong Lin Letters to the Editor 28 April 2021 Pages: 1454 - 1455
Author Correction to: Advances in anti-BRAF therapies for lung cancer Giandomenico RovielloAlberto D’AngeloNavid Sobhani Author Correction 01 March 2021 Pages: 1456 - 1456